Literature DB >> 11062724

Adamantyl maleimide induced changes in adhesion molecules and ROS are involved in apoptosis of human gastric cancer cells.

J J Wang1, T Y Liu, P H Yin, C W Wu, Y T Chern, C W Chi.   

Abstract

BACKGROUND: We have previously found that N-1-adamantyl maleimide (AMI) inhibited the growth of SC-M1 tumors in vitro and in vivo. The cytotoxicity of AMI on SC-M1 was accompanied by a decrease of adherent cells and the suppressive effect was associated with conformational changes in cell membrane protein. In order to determine the cellular targets of AMI in human gastric cancer SC-M1 cells, we examined AMI-induced changes in the levels of adhesion molecules CD29 (beta 1 integrin) and CD54 (ICAM-1) and GSH. In addition, we also analyzed changes of apoptosis markers such as annexin V binding to membrane and caspase 3 activity in SC-M1 cells after treatment with AMI.
MATERIALS AND METHODS: Changes in CD29, CD54, annexin V binding and GSH levels were examined using FITC-conjugated antibodies or fluorescence probes and flowcytometry. Caspase 3 activity was assayed with spectrofluorometry.
RESULTS: We found that the expression of CD29 and CD54 on SC-M1 was decreased and the caspase 3 activity was increased during the early apoptosis induced by AMI. Moreover, it was found that the GSH content of the cell was depleted within 30 minutes and then recovered.
CONCLUSION: These results suggest that the cell membrane proteins, such as adhesion molecules (CD29, CD54) and intracellular GSH, were the targets of AMI on SC-M1 cells. Since these membrane alterations were prior to apoptosis they may have transduced a death signal to SC-M1 cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062724

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  (3R,4R)-2,5-Dioxo-1-m-tolyl-3,4-diyl diacetate.

Authors:  Sara Naz; Javid Zaidi; Tahir Mehmood; Peter G Jones
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-06-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.